Atlas Trials

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Clinical trial NCT00153101 · COMPLETED

Trial details

NCT number
NCT00153101
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Cardiovascular Diseases
Start date
2001-11-01
Primary completion
2008-06-01
Enrollment
31546

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.